NCT01567423View on ClinicalTrials.gov

Efficacy Study of Amodiaquine-Artesunate and Artemether-Lumefantrine for the Treatment of Uncomplicated Malaria

NACompletedINTERVENTIONAL
Enrollment

301

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions
Malaria, Falciparum
Interventions
DRUG

ASAQ Winthrop® Sanofi Aventis

Artesunate 25mg / amodiaquine 67.5mg: 1 tab/day for 3 days in children 5 to 8.9 kg Artesunate 50mg / amodiaquine 135mg: 1 tab/day for 3 days in children 9 to 17.9 kg

DRUG

Coartem®, Novartis

"artemether 20 mg / lumefantrine 120 mg co-formulated tablets given as six twice-daily doses over three days:~1. tab/dose for children 5 to 14.9 kg (total 6 tabs)~2. tabs/dose for children 15 to 24.9 kg (total 12 tabs)"

Trial Locations (1)

Unknown

General reference hospital of Chamfubu, Pweto

Sponsors

Lead Sponsor

Epicentre
All Listed Sponsors
collaborator

Medecins Sans Frontieres, Spain

OTHER

lead

Epicentre

OTHER

NCT01567423 - Efficacy Study of Amodiaquine-Artesunate and Artemether-Lumefantrine for the Treatment of Uncomplicated Malaria | Biotech Hunter | Biotech Hunter